Cosmo Pharmaceuticals

cosmopharma.com

Cosmo is a specialty pharmaceutical company that aims to become a global leader in the market of optimized therapies for selected gastro-intestinal diseases. The company’s proprietary clinical development pipeline specifically addresses innovative treatments for gastro-intestinal diseases, specifically Inflammatory Bowel Diseases (IBD), colon infections and colon diagnosis, as well as selected topically treated Skin Disorders.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

ACACIA PHARMA COMPLETES DRAWDOWN FROM €25 MILLION LOAN FACILITY FROM COSMO PHARMACEUTICALS TO SUPPORT US LAUNCHES OF BARHEMSYS® AND BYFAVO™

Acacia Pharma Group plc | October 12, 2020

news image

Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures or cancer chemotherapy, announces that it has drawn down the remaining €10 million available under its unsecured €25 million loan facility with Cosm...

Read More

GROUND-BREAKING COLLABORATION TO OFFER NEW HEART DISEASE DRUG TO NHS PATIENTS

Pharmacy Business | January 14, 2020

news image

The government on Monday announced a collaboration with Novartis to launch a clinical trial for ‘yet to be approved’ drug inclisiran. The drug could benefit thousands of patients at risk of heart disease in coming years. The ground-breaking collaboration includes Novartis, NHS England and the National Institute for Health Research (NIHR) and Oxford University. The Department of Health and Social Care (DHSC) expects this to position the UK as a world-leading destination to develop cut...

Read More

CIVICA RX PARTNERS WITH THERMO FISHER SCIENTIFIC TO DEVELOP AND MANUFACTURE DRUGS WITH A HISTORY OF DRUG SHORTAGES

Business Wire Press Releases | January 16, 2020

news image

Today announced it has signed a long-term agreement with Thermo Fisher Scientific to develop and manufacture medications with Civica as the owner of the regulatory pathway. By working with Thermo Fisher to develop Civica-owned Abbreviated New Drug Applications (ANDAs), Civica will secure the manufacture of certain essential medications, further mitigating the risk of drug shortages in the future. This partnership has an initial seven-year term and represents a key component of Civica’s man...

Read More

OCUPHIRE PHARMA ANNOUNCES IN-LICENSE OF PHASE 2 ORAL SMALL MOLECULE DRUG CANDIDATE FOR DIABETIC RETINOPATHY

Business Wire | January 22, 2020

news image

Ocuphire Pharma, Inc., a clinical-stage pharmaceutical company focused on the development and commercialization of therapies to treat patients with a variety of ophthalmic disorders, today announced that it has entered into an agreement with Apexian Pharmaceuticals, Inc., granting Ocuphire an exclusive worldwide sublicense to Apexian’s Ref-1 Inhibitor program, including its lead drug candidate APX3330, for all ophthalmic and diabetic indications. APX3330 is a first-in-class, orally-adminis...

Read More
news image

ACACIA PHARMA COMPLETES DRAWDOWN FROM €25 MILLION LOAN FACILITY FROM COSMO PHARMACEUTICALS TO SUPPORT US LAUNCHES OF BARHEMSYS® AND BYFAVO™

Acacia Pharma Group plc | October 12, 2020

Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures or cancer chemotherapy, announces that it has drawn down the remaining €10 million available under its unsecured €25 million loan facility with Cosm...

Read More
news image

GROUND-BREAKING COLLABORATION TO OFFER NEW HEART DISEASE DRUG TO NHS PATIENTS

Pharmacy Business | January 14, 2020

The government on Monday announced a collaboration with Novartis to launch a clinical trial for ‘yet to be approved’ drug inclisiran. The drug could benefit thousands of patients at risk of heart disease in coming years. The ground-breaking collaboration includes Novartis, NHS England and the National Institute for Health Research (NIHR) and Oxford University. The Department of Health and Social Care (DHSC) expects this to position the UK as a world-leading destination to develop cut...

Read More
news image

CIVICA RX PARTNERS WITH THERMO FISHER SCIENTIFIC TO DEVELOP AND MANUFACTURE DRUGS WITH A HISTORY OF DRUG SHORTAGES

Business Wire Press Releases | January 16, 2020

Today announced it has signed a long-term agreement with Thermo Fisher Scientific to develop and manufacture medications with Civica as the owner of the regulatory pathway. By working with Thermo Fisher to develop Civica-owned Abbreviated New Drug Applications (ANDAs), Civica will secure the manufacture of certain essential medications, further mitigating the risk of drug shortages in the future. This partnership has an initial seven-year term and represents a key component of Civica’s man...

Read More
news image

OCUPHIRE PHARMA ANNOUNCES IN-LICENSE OF PHASE 2 ORAL SMALL MOLECULE DRUG CANDIDATE FOR DIABETIC RETINOPATHY

Business Wire | January 22, 2020

Ocuphire Pharma, Inc., a clinical-stage pharmaceutical company focused on the development and commercialization of therapies to treat patients with a variety of ophthalmic disorders, today announced that it has entered into an agreement with Apexian Pharmaceuticals, Inc., granting Ocuphire an exclusive worldwide sublicense to Apexian’s Ref-1 Inhibitor program, including its lead drug candidate APX3330, for all ophthalmic and diabetic indications. APX3330 is a first-in-class, orally-adminis...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us